Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Initial Beneficial Ownership · 3

ADARx Pharmaceuticals, Inc.

ADRXNASDAQEQUITYCurrent

Initial Beneficial Ownership

Filed Sep 24, 2026Accepted Sep 24, 2026, 7:05 PM EDTFiling CIK 1853723Accession 0001193125-26-401300
Share

Structured filing — 3

ownership.xml

Open full document ↗

Filing details

Report period
2026-09-24
Issuer
ADARx Pharmaceuticals, Inc.
Issuer CIK
0001802369
Trading symbol
ADRX

Reporting owner 1

Name
SR ONE CAPITAL MANAGEMENT, LLC
Reporting owner CIK
0001853723
Relationship
10% owner
Address
929 MAIN STREET, SUITE 200, REDWOOD CITY, CA, 94063

Derivative holdings

Derivative holdings · 6 reported rows
SecurityConversion / exercise priceExercisableExpiresUnderlying securityUnderlying sharesOwnershipNature of ownership
Series B Preferred Stock[F1][F1][F1]Common Stock3,334,938ISee Note 2[F2]
Series B-1 Preferred Stock[F1][F1][F1]Common Stock1,113,666ISee Note 2[F2]
Series C Preferred Stock[F1][F1][F1]Common Stock512,897ISee Note 2[F2]
Series C Preferred Stock[F1][F1][F1]Common Stock1,538,691ISee Note 3[F3]
Series B Preferred Stock[F1][F1][F1]Common Stock1,667,468ISee Note 4[F4]
Series B-1 Preferred Stock[F1][F1][F1]Common Stock169,001ISee Note 4[F4]
Table key
I
Indirect

Footnotes

F1
Each share of Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15↩ 16↩ 17↩ 18
F2
The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1↩ 2↩ 3
F3
The securities are directly held by SR One Capital Opportunities Fund I, LP ("SR One Opportunities Fund I"). SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I") is the sole general partner of SR One Opportunities Fund I, and SR One Capital Management is the sole general partner of SR One Opportunities Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Opportunities Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1
F4
The securities are directly held by SR One Co-Invest III, LLC ("SR One Co-Invest"). SR One Co-Invest III Manager LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1↩ 2

Signature 1

Signed
/s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC
Date
2026-09-24

Filed exhibits

Company context

We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by Li Zhen regarding ADARx Pharmaceuticals, Inc.Nov 13, 2026
  2. 10-Q filingNov 12, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureNov 12, 2026
  4. SCHEDULE 13G - filed by LAV Biosciences Fund V, L.P. regarding ADARx Pharmaceuticals, Inc.Oct 16, 2026
  5. SCHEDULE 13D - filed by ORBIMED ADVISORS LLC regarding ADARx Pharmaceuticals, Inc.Oct 2, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.